Guideline-driven intervention on SCI-associated dyslipidemia, metabolic syndrome, and glucose intolerance using pharmacological agents

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

This review summarizes current thinking and evidence-based recommendations for pharmacotherapy in the treatment of dyslipidemia, metabolic syndrome, and glucose intolerance as a basis for their application to individuals with a spinal cord injury (SCI). Although the evidence that subjects with an SCI are categorically at increased risk for cardiovascular disease is mixed, a significant number of such patients have cardiometabolic risk factors and therefore a systematic approach to this problem is important. The guidelines discussed are those recommended by the Adult Treatment Panel III of the National Cholesterol Education Program. These focus primarily on low-density lipoprotein LDL cholesterol (LDL-C). Several cardiometabolic risk factors such as hypertriglyceridemia, low high-density lipoprotein cholesterol (HDL-C), and glucose intolerance constitute possible targets for pharmacotherapy beyond LDL-C.

Original languageEnglish
Pages (from-to)46-57
Number of pages12
JournalTopics in Spinal Cord Injury Rehabilitation
Volume14
Issue number3
DOIs
StatePublished - Dec 1 2009

Fingerprint

Glucose Intolerance
Dyslipidemias
Spinal Cord Injuries
LDL Cholesterol
Pharmacology
Guidelines
Drug Therapy
Hypertriglyceridemia
HDL Cholesterol
Cardiovascular Diseases
Cholesterol
Education
Therapeutics

Keywords

  • Dyslipidemia
  • Glucose intolerance
  • Metabolic syndrome
  • Pharmacotherapy

ASJC Scopus subject areas

  • Clinical Neurology
  • Rehabilitation
  • Physical Therapy, Sports Therapy and Rehabilitation

Cite this

@article{3bff7a0e53da463f9731040d1da7ffc8,
title = "Guideline-driven intervention on SCI-associated dyslipidemia, metabolic syndrome, and glucose intolerance using pharmacological agents",
abstract = "This review summarizes current thinking and evidence-based recommendations for pharmacotherapy in the treatment of dyslipidemia, metabolic syndrome, and glucose intolerance as a basis for their application to individuals with a spinal cord injury (SCI). Although the evidence that subjects with an SCI are categorically at increased risk for cardiovascular disease is mixed, a significant number of such patients have cardiometabolic risk factors and therefore a systematic approach to this problem is important. The guidelines discussed are those recommended by the Adult Treatment Panel III of the National Cholesterol Education Program. These focus primarily on low-density lipoprotein LDL cholesterol (LDL-C). Several cardiometabolic risk factors such as hypertriglyceridemia, low high-density lipoprotein cholesterol (HDL-C), and glucose intolerance constitute possible targets for pharmacotherapy beyond LDL-C.",
keywords = "Dyslipidemia, Glucose intolerance, Metabolic syndrome, Pharmacotherapy",
author = "Goldberg, {Ronald B}",
year = "2009",
month = "12",
day = "1",
doi = "10.1310/sci1403-46",
language = "English",
volume = "14",
pages = "46--57",
journal = "Topics in Spinal Cord Injury Rehabilitation",
issn = "1082-0744",
publisher = "Thomas Land Publishers Inc.",
number = "3",

}

TY - JOUR

T1 - Guideline-driven intervention on SCI-associated dyslipidemia, metabolic syndrome, and glucose intolerance using pharmacological agents

AU - Goldberg, Ronald B

PY - 2009/12/1

Y1 - 2009/12/1

N2 - This review summarizes current thinking and evidence-based recommendations for pharmacotherapy in the treatment of dyslipidemia, metabolic syndrome, and glucose intolerance as a basis for their application to individuals with a spinal cord injury (SCI). Although the evidence that subjects with an SCI are categorically at increased risk for cardiovascular disease is mixed, a significant number of such patients have cardiometabolic risk factors and therefore a systematic approach to this problem is important. The guidelines discussed are those recommended by the Adult Treatment Panel III of the National Cholesterol Education Program. These focus primarily on low-density lipoprotein LDL cholesterol (LDL-C). Several cardiometabolic risk factors such as hypertriglyceridemia, low high-density lipoprotein cholesterol (HDL-C), and glucose intolerance constitute possible targets for pharmacotherapy beyond LDL-C.

AB - This review summarizes current thinking and evidence-based recommendations for pharmacotherapy in the treatment of dyslipidemia, metabolic syndrome, and glucose intolerance as a basis for their application to individuals with a spinal cord injury (SCI). Although the evidence that subjects with an SCI are categorically at increased risk for cardiovascular disease is mixed, a significant number of such patients have cardiometabolic risk factors and therefore a systematic approach to this problem is important. The guidelines discussed are those recommended by the Adult Treatment Panel III of the National Cholesterol Education Program. These focus primarily on low-density lipoprotein LDL cholesterol (LDL-C). Several cardiometabolic risk factors such as hypertriglyceridemia, low high-density lipoprotein cholesterol (HDL-C), and glucose intolerance constitute possible targets for pharmacotherapy beyond LDL-C.

KW - Dyslipidemia

KW - Glucose intolerance

KW - Metabolic syndrome

KW - Pharmacotherapy

UR - http://www.scopus.com/inward/record.url?scp=59849091218&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=59849091218&partnerID=8YFLogxK

U2 - 10.1310/sci1403-46

DO - 10.1310/sci1403-46

M3 - Article

AN - SCOPUS:59849091218

VL - 14

SP - 46

EP - 57

JO - Topics in Spinal Cord Injury Rehabilitation

JF - Topics in Spinal Cord Injury Rehabilitation

SN - 1082-0744

IS - 3

ER -